

IELSG INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP

TRIALS COORDINATION CENTRE: ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND
OSPEDALE SAN GIOVANNI - CH-6500 BELLINZONA - SWITZERLAND
E. ZUCCA, A. CONCONI, F. CAVALLI / C. MORININI, M. TROVESI
PHONE ++41 91 811 91 11 - FAX ++41 91 811 91 82 - E-MAIL ielsg@ticino.com - www.ielsg.org

NEWSLETTER 12

Bellinzona, October 2002

Dear colleagues and friends,

this is the first newsletter following our last meeting held in Lugano after the 8th International Conference on Malignant Lymphoma in the past June. Some of the topics discussed there are now getting mature and we want to drive your attention on a few issues.

1. IELSG 19 STUDY

Multicenter randomized trial of Chlorambucil versus Chlorambucil plus Rituximab in extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT lymphoma)

Approximately 200 patients will have to be randomized in order to detect a 20% improvement in event free survival. Rituximab for this study will be kindly provided free of charge by Roche International. All the MALT lymphoma patients with localised disease at any site who do not respond to local therapy, the H. pylori-negative gastric lymphomas or those who failed antibiotic therapy will be eligible as well as those with disseminated or multifocal MALT lymphoma at any extranodal site.

We will be ready to enter patients in the study within few weeks. We thank all the investigators who have already notified their intention to participate.

Because of insurance problems at present this study is limited to Western Europe, Australia and Canada. We plan to open the study to additional institutions from other countries (East Europe, Latin America, the USA, Asia ...) as soon as the insurance issue will be solved. The investigators who want to participate should require the protocol at the IELSG Trials Coordination Center.

2. ONGOING STUDIES

All protocols and CRFs will be provided upon request to ielsg@ticino.com. Protocols and CRFs of several IELSG retrospective studies can also be downloaded from www.ielsg.org.

The following studies are open for patient registration.

- IELSG 18 Retrospective survey of primary effusion lymphomas
- IELSG 17 Multi-institutional retrospective analysis of intravascular lymphomatosis
- IELSG 16 RT-PCR detection of the t(11;18) translocation as a predictor of outcome in extranodal marginal lymphoma of MALT type
- IELSG 15 Retrospective evaluation of primary breast lymphoma
- IELSG 14 Retrospective evaluation of primary bone lymphoma
- IELSG 12 Molecular characterisation of chromosome 11q amplification in primary extranodal diffuse large B-cell lymphomas
- IELSG 11 Retrospective evaluation of cutaneous B-cell lymphomas
- IELSG 10 Prospective study of R-CHOP plus radiotherapy and intrathecal prophylaxis in primary testicular diffuse large B-cell lymphoma
- IELSG 4 Prospective randomized trial of chemotherapy vs chemotherapy plus irradiation in localized primary gastric large B-cell lymphomas

3. SIXTH IELSG ANNUAL MEETING AND ESO COURSE ON MALIGNANT LYMPHOMA

The next IELSG meeting will be held in Ascona on March 7-8, 2003. This meeting will be followed by a ESO (European School of Oncology) Course on Malignant Lymphoma. Please find enclosed the programme of the course and the details for the registration.

Registration to the IELSG meeting is free, but, as in the past years, the total number of participants will be limited to 150 persons.

Early registrations will help the logistical organization of our meeting. Please register now using the following form.

4. ELECTRONIC NEWSLETTER AND THE WEBSITE

This is the last newsletter we are sending also by fax or mail. In the future the IELSG newsletter will circulate only by e-mail. Therefore, all those who thus far have received the newsletter by fax or mail will have to send us their proper e-mail address.

The IELSG newsletters are also posted in our website: www.ielsg.org. In the website you will also find detailed information on all the IELSG activities. Visit it!

5. IELSG PAPERS ACCEPTED FOR PUBLICATION

IELSG 1 STUDY

Zucca E, Conconi A, Pedrinis E, Cortelazzo S, Motta T, Gospodarowicz MK, Patterson BJ, Ferreri AJM, Ponzoni M, Devizzi L, Giardini R, Pinotti G, Capella C, Zinzani PL, Pileri S, Lopez-Guillermo A, Campo E, Ambrosetti A, Baldini L, Cavalli F on behalf of the International Extranodal Lymphoma Study Group (IELSG). Non-gastric marginal zone B-cell lymphoma of mucosa associated lymphoid tissue. **Accepted for publication in *Blood***

IELSG 5 STUDY

Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, Klasa R, Ozsahin , Mead GM, Gianni MA, Cortelazzo S, Ferreri AJM, Ambrosetti A, Martelli M, Thiéblemont C, Gomez Moreno H, Pinotti G, Martinelli G, Mozzana R, Grisanti S, Provencio M, Balzarotti M, Laveder F, Oltean G, Callea v, Cavalli F and Gospodarowicz MK on behalf of the International Extranodal Lymphoma Study Group (IELSG). Patterns of outcome and prognostic factors in primary large cell lymphoma of the testis in a survey of 373 patients by the International Extranodal Lymphoma Study Group (IELSG). **Accepted for publication in the *Journal of Clinical Oncology***

IELSG 7 STUDY

Ferreri AJM, Blay J-Y, Reni M, Pasini F, Spina M, Ambrosetti A, Calderoni A, Rossi A, Vavassori V, Conconi A, Devizzi L, Berger F, Ponzoni M, Borisch B, Tinguely M, Cerati M, Milani M, Orvieto E, Sanchez J, Chevreau Ch, Dell'Oro S, Zucca E, and Cavalli F on behalf of the International Extranodal Lymphoma Study Group (IELSG). A prognostic scoring system for primary central nervous system lymphomas: the IELSG experience on 378 immunocompetent patients. **Accepted for publication in the *Journal of Clinical Oncology***

IELSG 9 STUDY

Pileri SA, Gaidano G, Zinzani PL, Falini B, Gaulard P, Zucca E, Pieri F, Berra E, Sabattini E, Stefanò Ascani S, Piccioli M, Johnson PWM, Giardini R, Pescarmona E, Domenico Novero D, Piccaluga PP, Marafioti T, Alonso MA, Cavalli F. On behalf of the International Extranodal Lymphoma Study Group (IELSG). Primary mediastinal B-cell lymphoma (PMBL): High frequency of bcl-6 mutations and consistent expression of the transcription factors Oct-2, BOB.1 and PU.1 in the absence of immunoglobulins. **Accepted for publication in the *American Journal of Pathology***

IELSG 9 STUDY

Zinzani PL, Martelli M, Bertini M, Gianni AM, Devizzi L, Federico M, Pangalis G, Michels J, Zucca E, Cantonetti M, Cortelazzo S, Wotherspoon A, Ferreri AJM, Zaja F, Lauria F, De Renzo A, Liberati MA, Falini B, Balzarotti M, Calderoni A, Zaccaria A, Gentilini P, Fattori PP, Pavone E, Angelopoulou MK, Alinari L, Brugiatelli M, Di Renzo N, Bonifazi F, Pileri SA, Cavalli F. The International Extranodal Lymphoma Study Group (IELSG). Induction chemotherapy strategies for primary mediastinal large b-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients.

Accepted for publication in *Haematologica*

Best wishes

E. Zucca, F. Cavalli, C. Morinini, M. Trovesi

REGISTRATION FORM - SIXTH IELSG ANNUAL MEETING ASCONA (SWITZERLAND) MONTE VERITÀ - March 7- 8, 2003

1 Registration Form for each participant

Name

clinician pathologist other

Institution (full address)

.....

Contact phone

Fax

e-mail

will be attending the IELSG Ascona Meeting (March 7-8, 2003)

Hotel accommodation is required yes no

If yes specify:

single room double room shared with

(we suggest you, when possible, to share your room with a colleague)

Date of arrival

Date of departure

REGISTRATION CLOSING DATE: January 31, 2003

Please send back this filled Form to the IELSG coordination center

by e-mail ielsg@ticino.com or Fax N. ++41 91 811 91 82